Revenue CAGR of 18-20% aspirational over 5 years
Management reiterated the aspirational 18-20% CAGR target over a five-year horizon, though not linearly.
NEULANDLABORATORIES / guidance tracker
Keep management guidance in view.
Neuland Laboratories · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
Peptide facility operational by July 2026
The large-scale peptide commercial facility is on track for commissioning in July 2026 with project visibility.
Working capital normalization expected in FY27
Management expects working capital days to normalize in FY27 from the elevated 137 days in Q4.